Adenocarcinoma of the Esophagogastreal Junction, Cholangiocarcinoma, Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
Conditions
Brief summary
Recent pre-clinical data provide strong evidence that short-term starvation before the administration of cytostatic drugs for the chemotherapy of solid tumors leads to significantly higher efficacy and lower toxicity levels. However, these findings have so far not been validated in patients. The aim of this trial is to provide first clinical evidence regarding the impact of pre-chemotherapeutic short-term starvation on response to therapy (primary endpoint). Additionally, progression-free survival, adverse events, and overall survival will be monitored (secondary endpoints). In perspective, short-term starvation before chemotherapy could represent a simple and secure way to improve both efficacy and tolerance of chemotherapies at low cost.
Interventions
PROCEDUREStarvation
Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
Sponsors
University Hospital Tuebingen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient (male/female) ≥ 18 years of age 2. Written informed consent obtained prior to any trial specific procedure 3. Patient suffering from gastrointestinal tumors: Cholangiocarcinoma (CC), Pancreatic ductal adenocarcinoma (PDAC), Colorectal Cancer (CRC), Gastric Cancer (GC)/ Adenocarcinoma of the Esophagogastreal Junction (AEG) / Esophagus cancer (EC). 4. Planned to receive palliative chemotherapy 5. No prior palliative chemotherapy 6. ECOG performance status of 0 or 1 7. Life expectancy of 12 weeks or more 8. Adequate hematological parameters, as demonstrated by: * Hemoglobin \> 9.0 g/dl (5.6 mmol/l) * WBC ≥ 3.0 x 109/l * ANC ≥ 1500/mm³ * Platelets ≥ 75 x 109/l * S-creatinine ≤ 1.5 mg/dl (132 µmol/l)
Exclusion criteria
1. Underweight (BMI \< 18.5) 2. Dysphagia 3. Insulin-dependent diabetes mellitus 4. Renal failure requiring hemo- or peritoneal dialysis 5. Pregnant or breast-feeding women 6. Drug/alcohol abuse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1. | Three Months | Primary endpoint of this study is to assess the improvement in response to therapy for patients undergoing short-term starvation before chemotherapy of solid tumors in comparison to patients without dietary restrictions. Response to therapy on MRI or CT scancs will be measured using the RECIST criteria version 1.1. |
Outcome results
None listed